Nippon India Mutual Fund added over 0.56% of Piramal Pharma and now holds 1.56% of the company, representing 2,07,58,801 shares.
A pharmaceutical company operating across three major segments: contract development and manufacturing organisations, complex hospital generics for critical care, and consumer healthcare products. Established through the acquisition of Nicholas Laboratories in 1988, the company has expanded via strategic mergers and acquisitions alongside organic growth initiatives. It serves healthcare providers and consumers across India through its diversified business operations and specialized pharmaceutical solutions.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.
